|
US4584404A
(en)
*
|
1974-01-10 |
1986-04-22 |
Eli Lilly And Company |
Substituted phenoxyphenylproply dimethylamines
|
|
US4626549A
(en)
*
|
1974-01-10 |
1986-12-02 |
Eli Lilly And Company |
Treatment of obesity with aryloxyphenylpropylamines
|
|
JPS5283811A
(en)
*
|
1976-01-01 |
1977-07-13 |
Lilly Co Eli |
Aryloxy phenyl propylamines and their salts
|
|
GB1570613A
(en)
*
|
1976-10-27 |
1980-07-02 |
Akzo Nv |
Biologically active tricyclic compounds and pharmaceutical compositions containing same
|
|
IL56369A
(en)
*
|
1978-01-20 |
1984-05-31 |
Erba Farmitalia |
Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
|
|
FR2432500A1
(fr)
*
|
1978-02-24 |
1980-02-29 |
Roussel Uclaf |
Nouveaux derives de la benzene propanamine et leurs sels, procede de preparation et application a titre de medicaments
|
|
FR2455571A2
(fr)
*
|
1979-02-15 |
1980-11-28 |
Roussel Uclaf |
Nouveaux derives de la benzene propanamine et leurs sels, procede de preparation et application a titre medicaments
|
|
DE3017812A1
(de)
*
|
1980-05-09 |
1981-11-12 |
Merck Patent Gmbh, 6100 Darmstadt |
Cyclopropanderivate, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung
|
|
US4430319A
(en)
|
1982-05-21 |
1984-02-07 |
State University Of New York |
Radioactive iodine labeled phenolic amines
|
|
US4692469A
(en)
*
|
1982-09-07 |
1987-09-08 |
Ciba-Geigy Corporation |
Propylamine derivatives
|
|
US4824868A
(en)
*
|
1982-09-07 |
1989-04-25 |
Ciba-Geigy Corporation |
Propylamine derivatives useful for the treatment of dementia
|
|
US4590213A
(en)
*
|
1983-04-08 |
1986-05-20 |
Eli Lilly And Company |
Anti-anxiety method
|
|
HU207282B
(en)
*
|
1984-05-31 |
1993-03-29 |
Chinoin Gyogyszer Es Vegyeszet |
Process for producing phenyl-alkyl-amine derivatives and pharmaceutical compositions containing them
|
|
US4683235A
(en)
*
|
1985-02-25 |
1987-07-28 |
Eli Lilly And Company |
Analgesic method
|
|
US4594358A
(en)
*
|
1985-02-25 |
1986-06-10 |
Eli Lilly And Company |
Analgesic method
|
|
US4777291A
(en)
*
|
1985-02-27 |
1988-10-11 |
Eli Lilly And Company |
Racemization process
|
|
US4956388A
(en)
*
|
1986-12-22 |
1990-09-11 |
Eli Lilly And Company |
3-aryloxy-3-substituted propanamines
|
|
US5135947A
(en)
*
|
1987-04-09 |
1992-08-04 |
Eli Lilly And Company |
1-phenyl-3-naphthalenyloxypropanamines and their use as selective serotonin reuptake inhibitors
|
|
US5149714A
(en)
*
|
1987-08-14 |
1992-09-22 |
Merrell Dow Pharmaceuticals Inc. |
Antidepressants
|
|
CA1327795C
(en)
*
|
1987-08-14 |
1994-03-15 |
Jules Freedman |
Antidepressants which are aryloxy inadanamines
|
|
US4971998A
(en)
*
|
1987-10-22 |
1990-11-20 |
Massachusetts Institute Of Technology |
Methods for treating the premenstrual or late luteal phase syndrome
|
|
US5223540A
(en)
*
|
1987-10-22 |
1993-06-29 |
Massachusetts Institute Of Technology |
Method for treating the premenstrual or late luteal phase syndrome
|
|
US4876282A
(en)
*
|
1987-11-25 |
1989-10-24 |
Eli Lilly And Company |
1-Phenylalkylamines as selective serotonin uptake inhibitors
|
|
US4996235A
(en)
*
|
1987-11-25 |
1991-02-26 |
Eli Lilly And Company |
3,4-diphenylbutanamines
|
|
US5238959A
(en)
*
|
1988-04-08 |
1993-08-24 |
Eli Lilly And Company |
3-phenyloxy-3-phenyl propanamines
|
|
ZA892517B
(en)
*
|
1988-04-08 |
1990-12-28 |
Lilly Co Eli |
Propanamine derivatives
|
|
US5250571A
(en)
*
|
1988-11-14 |
1993-10-05 |
Eli Lilly And Company |
(S)-norfluoxetine in method of inhibiting serotonin uptake
|
|
US4902710A
(en)
*
|
1988-12-14 |
1990-02-20 |
Eli Lilly And Company |
Serotonin and norepinephrine uptake inhibitors
|
|
US5114976A
(en)
*
|
1989-01-06 |
1992-05-19 |
Norden Michael J |
Method for treating certain psychiatric disorders and certain psychiatric symptoms
|
|
IT1228209B
(it)
*
|
1989-01-10 |
1991-06-05 |
Grato Magnone |
Procedimento per la preparazione di fluoxetina cloridrato.
|
|
US5166437A
(en)
*
|
1989-03-03 |
1992-11-24 |
Orion-Yhtyma Oy |
Process for the preparation of fluoxetine
|
|
FI81083C
(fi)
*
|
1989-03-03 |
1990-09-10 |
Orion Yhtymae Oy |
Ett foerbaettrat foerfarande foer framstaellning av n-metyl-3-(p-trifluormetylfenoxi)-3-fenylpropylamin hydroklorid.
|
|
DK258389D0
(da)
*
|
1989-05-26 |
1989-05-26 |
Ferrosan As |
Aryloxyphenylpropylaminer, deres fremstilling og anvendelse
|
|
JPH0375680U
(US08066781-20111129-C00013.png)
*
|
1989-11-21 |
1991-07-30 |
|
|
|
US5021426A
(en)
*
|
1990-02-26 |
1991-06-04 |
Merck & Co., Inc. |
Method of traeting malaria with cyproheptadine derivatives
|
|
US5356934A
(en)
*
|
1990-03-29 |
1994-10-18 |
Eli Lilly And Company |
Selected serotonin subtype receptor agonist to treat sleep apnea
|
|
US5250572A
(en)
*
|
1990-03-29 |
1993-10-05 |
Eli Lilly And Company |
(R)-norfluoxetine in method for occupying serotonin IC receptors
|
|
US5589511A
(en)
*
|
1990-08-13 |
1996-12-31 |
Sepracor Inc. |
Method for treating migraine headaches using optically pure S(+) fluoxetine
|
|
US5708035A
(en)
*
|
1991-02-04 |
1998-01-13 |
Sepracor Inc. |
Methods of use and compositions of R(-) fluoxetine
|
|
AU642582B2
(en)
*
|
1991-02-25 |
1993-10-21 |
Eli Lilly And Company |
Treatment of lower urinary tract disorders
|
|
US5136078A
(en)
*
|
1991-02-26 |
1992-08-04 |
Eli Lilly And Company |
Synthesis of b-cyanohydrins
|
|
US5136079A
(en)
*
|
1991-02-26 |
1992-08-04 |
Eli Lilly And Company |
Regioselective synthesis
|
|
US5320825A
(en)
*
|
1991-05-01 |
1994-06-14 |
Trustees Of The University Of Pennsylvania |
Serotonin reuptake inhibitors for S.P.E.C.T. imaging
|
|
WO1993000811A1
(en)
*
|
1991-07-01 |
1993-01-21 |
The General Hospital Corporation |
Invertebrate phenylethanolamine transporter and the use thereof
|
|
IL99316A
(en)
*
|
1991-08-27 |
1995-03-15 |
Teva Pharma |
Production of fluoxetine and new intermediates
|
|
US5202319A
(en)
*
|
1991-09-23 |
1993-04-13 |
Hoechst-Roussel Pharmaceuticals Inc. |
Substituted 3-amino-2,3,4,5-tetrahydro-1-aryloxy-3-benzazepines
|
|
US5281624A
(en)
*
|
1991-09-27 |
1994-01-25 |
Eli Lilly And Company |
N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
|
|
DK0537915T3
(da)
*
|
1991-09-27 |
1995-11-27 |
Lilly Co Eli |
N-alkyl-3-phenyl-3-(2-alkylthiophenoxy)propylaminer som inhibitorer for epinephrin
|
|
HU9202128D0
(en)
*
|
1992-06-26 |
1992-10-28 |
Richter Gedeon Vegyeszet |
Method for producing n-methyl-(3-phenyl-3-(4-[trifluoro-methyl])-phenooxi-)-amine
|
|
EP0576766A1
(en)
*
|
1992-06-29 |
1994-01-05 |
Novo Nordisk A/S |
Propanolamine derivatives, their preparation and use
|
|
US7087765B2
(en)
*
|
1995-06-07 |
2006-08-08 |
Nps Pharmaceuticals, Inc. |
Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
|
|
US6017965A
(en)
*
|
1993-02-08 |
2000-01-25 |
Nps Pharmaceuticals, Inc. |
Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
|
|
TW344661B
(en)
*
|
1993-11-24 |
1998-11-11 |
Lilly Co Eli |
Pharmaceutical composition for treatment of incontinence
|
|
CA2134038C
(en)
*
|
1994-06-16 |
1997-06-03 |
David Taiwai Wong |
Potentiation of drug response
|
|
ES2082723B1
(es)
*
|
1994-07-20 |
1996-10-01 |
Lilly Sa |
Formulacion farmaceutica de fluoxetina en forma dispersable.
|
|
EP0714663A3
(en)
|
1994-11-28 |
1997-01-15 |
Lilly Co Eli |
Potentiation of drug responses by serotonin 1A receptor antagonists
|
|
US5576321A
(en)
*
|
1995-01-17 |
1996-11-19 |
Eli Lilly And Company |
Compounds having effects on serotonin-related systems
|
|
US5741789A
(en)
|
1995-01-17 |
1998-04-21 |
Eli Lilly And Company |
Compounds having effects on serotonin-related systems
|
|
ES2101650B1
(es)
*
|
1995-06-29 |
1998-01-16 |
Lilly Sa |
Procedimiento de preparacion de n-metil-3-fenil-3-(p-trifluorometilfenoxi) propilamina.
|
|
US6548084B2
(en)
*
|
1995-07-20 |
2003-04-15 |
Smithkline Beecham Plc |
Controlled release compositions
|
|
ES2101654B1
(es)
*
|
1995-07-24 |
1998-01-16 |
Lilly Sa |
Procedimiento de preparacion de n-metil-3-fenil-3-(p-trifluorometilfe noxi) propilamina.
|
|
ES2101655B1
(es)
*
|
1995-07-28 |
1998-01-16 |
Lilly Sa |
Procedimiento de preparacion de n-metil-3-fenil-3-(p-trifluorometilfe noxi) propilamina.
|
|
ES2103680B1
(es)
*
|
1995-08-03 |
1998-04-01 |
Lilly Sa |
Procedimiento de preparacion de n-metil-3-fenil-3- (p-trifluorometilfenoxi)propilamina.
|
|
EP0759299B1
(en)
*
|
1995-08-16 |
2000-04-26 |
Eli Lilly And Company |
Potentiation of serotonin response
|
|
ES2103681B1
(es)
*
|
1995-09-19 |
1998-04-01 |
Lilly Sa |
Procedimiento de preparacion de n-metil-3-fenil - (p-trifluorometilfenoxi) propilamina.
|
|
IT1283141B1
(it)
*
|
1996-07-11 |
1998-04-07 |
Laporte Organics Francis S P A |
Procedimento per la preparazione di n-metil-3-(p-trifluorometilfenossi)-3-fenilpropilamina e dei suoi
|
|
US6512010B1
(en)
|
1996-07-15 |
2003-01-28 |
Alza Corporation |
Formulations for the administration of fluoxetine
|
|
US5830500A
(en)
*
|
1996-07-22 |
1998-11-03 |
Pentech Pharmaceuticals, Inc. |
Low dose fluoxetine tablet
|
|
ZA977967B
(en)
*
|
1996-09-23 |
1999-03-04 |
Lilly Co Eli |
Combination therapy for treatment of psychoses
|
|
US6203817B1
(en)
|
1997-02-19 |
2001-03-20 |
Alza Corporation |
Reduction of skin reactions caused by transdermal drug delivery
|
|
US5910319A
(en)
|
1997-05-29 |
1999-06-08 |
Eli Lilly And Company |
Fluoxetine enteric pellets and methods for their preparation and use
|
|
PT1030667E
(pt)
*
|
1997-11-14 |
2005-06-30 |
Akzo Nobel Nv |
Utilizacao de mirtazapina para o fabrico de um medicamento para o tratamento de apenas do sono
|
|
US5936124A
(en)
*
|
1998-06-22 |
1999-08-10 |
Sepacor Inc. |
Fluoxetine process from benzoylpropionic acid
|
|
US6025517A
(en)
*
|
1998-08-03 |
2000-02-15 |
Sepracor Inc. |
Fluoxetine process from benzoylacetonitrile
|
|
WO2000041684A1
(en)
*
|
1999-01-13 |
2000-07-20 |
Warner-Lambert Company |
A pharmaceutical combination for the treatment of depression
|
|
FR2791345B1
(fr)
*
|
1999-03-26 |
2001-05-04 |
Adir |
Nouveaux derives du benzo[3,4]cyclobuta[1,2-c]pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
|
WO2000058262A1
(en)
*
|
1999-03-29 |
2000-10-05 |
Eli Lilly And Company |
Stereospecific method for preparing tomoxetine and intermediates thereof
|
|
CA2383785C
(en)
*
|
1999-09-03 |
2009-02-17 |
Eli Lilly And Company |
Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
|
|
WO2001044166A1
(en)
|
1999-12-17 |
2001-06-21 |
Ranbaxy Laboratories Limited |
Process for the preparation of fluoxetine hydrochloride
|
|
GB0004153D0
(en)
*
|
2000-02-23 |
2000-04-12 |
Astrazeneca Uk Ltd |
Novel use
|
|
GB0004152D0
(en)
*
|
2000-02-23 |
2000-04-12 |
Astrazeneca Uk Ltd |
Novel compounds
|
|
GB0004149D0
(en)
*
|
2000-02-23 |
2000-04-12 |
Astrazeneca Uk Ltd |
Novel compounds
|
|
GB0004151D0
(en)
*
|
2000-02-23 |
2000-04-12 |
Astrazeneca Uk Ltd |
Novel use
|
|
US6273260B1
(en)
|
2000-03-08 |
2001-08-14 |
Eli Lilly And Company |
Pharmaceutical packaging system
|
|
GB2357762B
(en)
*
|
2000-03-13 |
2002-01-30 |
Lundbeck & Co As H |
Crystalline base of citalopram
|
|
WO2001078721A1
(en)
*
|
2000-04-13 |
2001-10-25 |
Mayo Foundation For Medical Education And Research |
Aβ42 LOWERING AGENTS
|
|
IL139975A0
(en)
*
|
2000-11-29 |
2002-02-10 |
Univ Ramot |
Anti proliferative drugs
|
|
US20050013853A1
(en)
*
|
2000-11-29 |
2005-01-20 |
Irit Gil-Ad |
Anti-proliferative drugs
|
|
US6316672B1
(en)
|
2001-01-31 |
2001-11-13 |
Grayson Walker Stowell |
Form a of fluoxetine hydrochloride
|
|
US6313350B1
(en)
|
2001-01-31 |
2001-11-06 |
Grayson Walker Stowell |
Form a of fluoxetine hydrochloride
|
|
US6310251B1
(en)
|
2001-01-31 |
2001-10-30 |
Grayson Walker Stowell |
Form a of fluoxetine hydrochloride
|
|
US6258853B1
(en)
|
2001-01-31 |
2001-07-10 |
Grayson Walker Stowell |
Form a of fluoxetine hydrochloride
|
|
US6310250B1
(en)
|
2001-01-31 |
2001-10-30 |
Grayson Walker Stowell |
Form A of fluoxetine hydrochloride
|
|
SK10632003A3
(sk)
*
|
2001-03-06 |
2004-06-08 |
Eli Lilly And Company |
Inhibítor príjmu monoamínov
|
|
US6645946B1
(en)
|
2001-03-27 |
2003-11-11 |
Pro-Pharmaceuticals, Inc. |
Delivery of a therapeutic agent in a formulation for reduced toxicity
|
|
AR035700A1
(es)
*
|
2001-05-08 |
2004-06-23 |
Astrazeneca Ab |
Derivados de arilheteroalquilamina, composicion farmaceutica, usos de estos derivados para la fabricacion de medicamentos, metodos de tratamiento, y proceso para la preparacion de estos derivados
|
|
US7034059B2
(en)
*
|
2001-07-02 |
2006-04-25 |
Sepracor Inc. |
Methods of using norfluoxetine
|
|
DE60234057D1
(de)
|
2001-07-25 |
2009-11-26 |
Raptor Pharmaceutical Inc |
Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
|
|
WO2003011272A1
(en)
*
|
2001-07-31 |
2003-02-13 |
Pharmacia & Upjohn Company |
Treatment of chronic pain with 3-aryloxy-3-phenylpropanamines
|
|
SE0102641D0
(sv)
*
|
2001-07-31 |
2001-07-31 |
Astrazeneca Ab |
Novel compounds
|
|
SE0102640D0
(sv)
*
|
2001-07-31 |
2001-07-31 |
Astrazeneca Ab |
Novel compounds
|
|
US20040170688A1
(en)
*
|
2001-08-06 |
2004-09-02 |
Deshmukh Abhijit Mukund |
Enteric formulation of fluoxetin
|
|
WO2003013480A1
(en)
|
2001-08-06 |
2003-02-20 |
Dr. Reddy's Laboratories Ltd. |
Improved enteric formulation of fluoxetin
|
|
US6630454B2
(en)
|
2001-09-10 |
2003-10-07 |
Ramot At Tel-Aviv University Ltd. |
Method and pharmaceutical composition for the treatment of cancer
|
|
CN101921267A
(zh)
*
|
2001-10-12 |
2010-12-22 |
阿泽范药品公司 |
β-内酰胺后叶加压素V1a拮抗剂
|
|
US20040034106A1
(en)
*
|
2001-11-06 |
2004-02-19 |
Read Holly Ann |
Treatment of anxiety disorders
|
|
AU2002347984A1
(en)
*
|
2001-11-30 |
2003-06-17 |
Eli Lilly And Company |
Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
|
|
US20050009925A1
(en)
*
|
2001-12-11 |
2005-01-13 |
Bymaster Franklin Porter |
Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure
|
|
EP2266590A3
(en)
|
2002-02-22 |
2011-04-20 |
Shire LLC |
Active agent delivery sytems and methods for protecting and administering active agents
|
|
US7326733B2
(en)
*
|
2002-05-31 |
2008-02-05 |
The Forsyth Institute |
Methods for increasing bone density
|
|
JP2004077714A
(ja)
*
|
2002-08-15 |
2004-03-11 |
Fuji Xerox Co Ltd |
光走査装置
|
|
SE0203304D0
(sv)
*
|
2002-11-07 |
2002-11-07 |
Astrazeneca Ab |
Novel Coumpounds
|
|
US6846957B2
(en)
*
|
2002-11-22 |
2005-01-25 |
Board Of Regents, The University Of Texas System |
Synthesis of 3-aminomethyl-1-propanol, a fluoxetine precursor
|
|
US20040235925A1
(en)
*
|
2002-12-17 |
2004-11-25 |
Pharmacia Corporation |
Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
|
|
EP1603548A4
(en)
*
|
2003-02-05 |
2007-10-10 |
Myriad Genetics Inc |
COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS
|
|
MXPA05011225A
(es)
*
|
2003-04-18 |
2005-12-14 |
Pharmacia & Upjohn Co Llc |
Politerapias.
|
|
SG141430A1
(en)
*
|
2003-05-30 |
2008-04-28 |
Ranbaxy Lab Ltd |
Substituted pyrrole derivatives and their use as hmg-co inhibitors
|
|
US20050042284A1
(en)
*
|
2003-07-11 |
2005-02-24 |
Myriad Genetics, Incorporated |
Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
|
|
WO2005011583A2
(en)
*
|
2003-07-28 |
2005-02-10 |
Leslie Joe Dunaway |
Treatment of allergic rhinitis and asthma
|
|
CA2537402C
(en)
|
2003-09-12 |
2009-05-05 |
Pfizer Inc. |
Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
|
|
CN103788089A
(zh)
*
|
2003-09-17 |
2014-05-14 |
詹森药业有限公司 |
作为血清素受体调节剂的稠合杂环化合物
|
|
CA2547283C
(en)
*
|
2003-11-26 |
2010-11-09 |
Pfizer Products Inc. |
Aminopyrazole derivatives as gsk-3 inhibitors
|
|
EP2343073A3
(en)
|
2003-12-11 |
2011-10-12 |
Sepracor Inc. |
Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
|
|
ES2390879T3
(es)
*
|
2003-12-31 |
2012-11-19 |
Actavis Group Ptc Ehf. |
Formulaciones de atomoxetina
|
|
EP1732610A2
(en)
*
|
2004-03-26 |
2006-12-20 |
Baylor University |
Targeted serotonin reuptake inhibitors
|
|
WO2006001877A2
(en)
*
|
2004-04-13 |
2006-01-05 |
Myriad Genetics, Inc. |
Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
|
|
WO2005102366A2
(en)
*
|
2004-04-19 |
2005-11-03 |
Philip Maxwell Satow |
Lithium combinations, and uses related thereto
|
|
AU2005241023A1
(en)
*
|
2004-04-29 |
2005-11-17 |
Keystone Retaining Wall Systems, Inc. |
Veneers for walls, retaining walls and the like
|
|
CA2618985A1
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
|
WO2006020850A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
|
WO2006020852A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
|
EP1794112A4
(en)
*
|
2004-09-27 |
2009-11-04 |
Reddys Lab Ltd Dr |
SYNTHESIS OF ATOMEXETINE HYDROCHLORIDE
|
|
TWI306858B
(en)
*
|
2004-12-23 |
2009-03-01 |
Teva Pharma |
Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof
|
|
EP1856087A1
(en)
*
|
2005-03-08 |
2007-11-21 |
Teva Pharmaceutical Industries Limited |
Crystal forms of (s)-(+)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl) propanamine oxalate and the preparation thereof
|
|
EP1858873A2
(en)
*
|
2005-03-14 |
2007-11-28 |
Teva Pharmaceutical Industries Ltd |
Process for the purification of duloxetine hydrochloride
|
|
EP1868434A4
(en)
|
2005-03-22 |
2011-10-26 |
Azevan Pharmaceuticals Inc |
BETA-LACTAMYL ALKANIC ACIDS FOR THE TREATMENT OF PREMIERSTRUELLEN FAULTS
|
|
MX2007012936A
(es)
*
|
2005-04-22 |
2008-01-11 |
Wyeth Corp |
Derivados de dihidrobenzofurano y usos de los mismos.
|
|
PE20061319A1
(es)
*
|
2005-04-22 |
2006-12-28 |
Wyeth Corp |
Cristales formados de clorhidrato de {[(2r)-7-(2,6-diclorofenil)-5-fluoro-2-3-dihidro-1-benzofurano-2-il]metil}amina
|
|
AU2006239922A1
(en)
*
|
2005-04-22 |
2006-11-02 |
Wyeth |
Benzofuranyl alkanamine derivatives and uses thereof as 5-HT2c agonists
|
|
MX2007012883A
(es)
|
2005-04-22 |
2007-12-10 |
Wyeth Corp |
Derivados de dihidrobenzofurano y usos de los mismos.
|
|
CN103259027A
(zh)
|
2005-04-28 |
2013-08-21 |
普罗透斯数字保健公司 |
药物信息系统
|
|
SG163588A1
(en)
|
2005-07-08 |
2010-08-30 |
Braincells Inc |
Methods for identifying agents and conditions that modulate neurogenesis
|
|
US7485754B2
(en)
*
|
2005-07-08 |
2009-02-03 |
Apotex Pharmachem Inc. |
Efficient method for preparing 3-aryloxy-3-arylpropylamines and their optical stereoisomers
|
|
US20070015832A1
(en)
*
|
2005-07-14 |
2007-01-18 |
Myriad Genetics, Incorporated |
Methods of treating overactive bladder and urinary incontinence
|
|
US8048874B2
(en)
|
2005-07-19 |
2011-11-01 |
Azevan Pharmaceuticals, Inc. |
Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists
|
|
KR20080039876A
(ko)
*
|
2005-07-22 |
2008-05-07 |
미리어드 제네틱스, 인크. |
높은 약물 충진 제형 및 투여형
|
|
US7598255B2
(en)
*
|
2005-08-04 |
2009-10-06 |
Janssen Pharmaceutica Nv |
Pyrimidine compounds as serotonin receptor modulators
|
|
EP2258358A3
(en)
|
2005-08-26 |
2011-09-07 |
Braincells, Inc. |
Neurogenesis with acetylcholinesterase inhibitor
|
|
US20080207923A1
(en)
*
|
2005-09-22 |
2008-08-28 |
Santiago Ini |
Pure DNT-maleate and methods of preparation thereof
|
|
EP1838692A2
(en)
*
|
2005-09-22 |
2007-10-03 |
Teva Pharmaceutical Industries Ltd |
Dnt-maleate and methods of preparation thereof
|
|
CA2625153A1
(en)
|
2005-10-21 |
2007-04-26 |
Braincells, Inc. |
Modulation of neurogenesis by pde inhibition
|
|
JP2009513672A
(ja)
|
2005-10-31 |
2009-04-02 |
ブレインセルス，インコーポレイティド |
神経発生のｇａｂａ受容体媒介調節
|
|
AU2006313430B2
(en)
*
|
2005-11-08 |
2012-09-06 |
Ranbaxy Laboratories Limited |
Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
|
|
CN1304360C
(zh)
*
|
2005-12-12 |
2007-03-14 |
天津大学 |
N,n－二甲基－3－羟基－3－芳基丙胺的制备方法
|
|
WO2007086948A1
(en)
*
|
2006-01-23 |
2007-08-02 |
Teva Pharmaceutical Industries Ltd. |
Dnt-fumarate and methods of preparation thereof
|
|
FR2912057B1
(fr)
*
|
2007-02-07 |
2009-04-17 |
Sanofi Aventis Sa |
Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
|
|
WO2007104035A1
(en)
*
|
2006-03-08 |
2007-09-13 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
|
CL2007000667A1
(es)
*
|
2006-03-14 |
2008-03-14 |
Ranbaxi Lab Ltd |
Composicion farmaceutica que comprende al acido 7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]pirrol-1-il]-3,5-dihidroxi-heptanoico o una sal y al menos un agente estabilizante; procedimiento de preparacion, util en e
|
|
TW200806300A
(en)
*
|
2006-03-24 |
2008-02-01 |
Wyeth Corp |
New therapeutic combinations for the treatment of depression
|
|
CA2651862A1
(en)
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
5 ht receptor mediated neurogenesis
|
|
US20100009983A1
(en)
*
|
2006-05-09 |
2010-01-14 |
Braincells, Inc. |
5 ht receptor mediated neurogenesis
|
|
US7858611B2
(en)
*
|
2006-05-09 |
2010-12-28 |
Braincells Inc. |
Neurogenesis by modulating angiotensin
|
|
EP2021000A2
(en)
|
2006-05-09 |
2009-02-11 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
|
CN101448815A
(zh)
*
|
2006-05-23 |
2009-06-03 |
特瓦制药工业有限公司 |
度洛西汀hci多晶型物
|
|
US20080033045A1
(en)
*
|
2006-07-07 |
2008-02-07 |
Myriad Genetics, Incorporated |
Treatment of psychiatric disorders
|
|
AU2007274724B2
(en)
*
|
2006-07-14 |
2012-07-26 |
Ranbaxy Laboratories Limited |
Polymorphic forms of an HMG-CoA reductase inhibitor and uses thereof
|
|
TW200817003A
(en)
*
|
2006-07-31 |
2008-04-16 |
Sanofi Aventis |
Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
|
|
WO2008026227A2
(en)
*
|
2006-08-28 |
2008-03-06 |
Matrix Laboratories Ltd |
A process for the preparation of atomoxetine hydrochloride
|
|
AU2007292848A1
(en)
*
|
2006-09-08 |
2008-03-13 |
Braincells, Inc. |
Combinations containing a 4-acylaminopyridine derivative
|
|
US20100016274A1
(en)
*
|
2006-09-14 |
2010-01-21 |
Koppel Gary A |
Beta-lactam cannabinoid receptor modulators
|
|
EP2063905B1
(en)
|
2006-09-18 |
2014-07-30 |
Raptor Pharmaceutical Inc |
Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
|
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
|
US20080103165A1
(en)
*
|
2006-09-19 |
2008-05-01 |
Braincells, Inc. |
Ppar mediated modulation of neurogenesis
|
|
ITMI20061987A1
(it)
*
|
2006-10-16 |
2008-04-17 |
Archimica Srl |
Processo per la sintesi di arilossipropilammine ed eteroarilossipropilammine.
|
|
WO2008062473A1
(en)
*
|
2006-10-31 |
2008-05-29 |
Cadila Healthcare Limited |
Process for preparing atomoxetine hydrochloride
|
|
FR2910319B1
(fr)
|
2006-12-20 |
2011-06-03 |
Substipharm Dev |
Formulations pharmaceutiques dispersibles contenant de la fluoxetine
|
|
WO2008083204A2
(en)
*
|
2006-12-28 |
2008-07-10 |
Braincells, Inc. |
Modulation of neurogenesis by melatoninergic ligands
|
|
US20080171750A1
(en)
*
|
2007-01-11 |
2008-07-17 |
Braincells, Inc. |
Modulation Of Neurogenesis With Use of Modafinil
|
|
WO2008122019A1
(en)
*
|
2007-04-02 |
2008-10-09 |
Cypress Biosciences, Inc. |
Improving the tolerability of both mirtazapine and reboxetine by using them in combination
|
|
EP3524248A1
(en)
|
2007-06-21 |
2019-08-14 |
VeroScience LLC |
Method of treating metabolic disorders and depression with dopamine receptor agonists
|
|
WO2009141833A2
(en)
*
|
2008-04-17 |
2009-11-26 |
Ind-Swift Laboratories Limited |
An improved process for synthesizing highly pure atomoxetine
|
|
WO2009128058A1
(en)
|
2008-04-18 |
2009-10-22 |
UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al |
Psycho-pharmaceuticals
|
|
PL3395372T3
(pl)
|
2009-02-20 |
2022-07-25 |
EnhanX Biopharm Inc. |
Układ do dostarczania leków na bazie glutationu
|
|
US20100216805A1
(en)
|
2009-02-25 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
|
KR20190116576A
(ko)
|
2009-05-06 |
2019-10-14 |
라보라토리 스킨 케어, 인크. |
활성제-칼슘 포스페이트 입자 복합체를 포함하는 피부 전달 조성물 및 이들을 이용하는 방법
|
|
WO2011027359A2
(en)
|
2009-07-30 |
2011-03-10 |
Matrix Laboratories Ltd |
Novel process for the preparation of 4-hydroxy atomoxetine
|
|
EP2348120B1
(en)
|
2009-12-30 |
2014-06-11 |
Universität Wien |
Enzymatic reduction of 1-phenylpropanone and derivatives thereof
|
|
EP2587919B1
(en)
|
2010-07-01 |
2017-12-13 |
Azevan Pharmaceuticals, Inc. |
Methods for treating post traumatic stress disorder
|
|
WO2012020418A1
(en)
|
2010-08-12 |
2012-02-16 |
Matrix Laboratories Ltd |
Novel polymorphs of 4-hydroxy atomoxetine hydrochloride
|
|
US20120077778A1
(en)
|
2010-09-29 |
2012-03-29 |
Andrea Bourdelais |
Ladder-Frame Polyether Conjugates
|
|
KR20140045925A
(ko)
|
2011-03-17 |
2014-04-17 |
루핀 리미티드 |
선택적 세로토닌 재흡수 억제제의 방출조절형 약제학적 조성물
|
|
EA201590044A1
(ru)
|
2012-07-31 |
2015-09-30 |
Сановел Хайван Саглиги Юрюнлери Санайи Ве Тиджарет А.С. |
Применение флуоксетина у животных
|
|
EA201590047A1
(ru)
|
2012-07-31 |
2015-09-30 |
Сановел Хайван Саглиги Юрюнлери Санайи Ве Тиджарет А.С. |
Применение флуоксетина для увеличения мясной и молочной продуктивности
|
|
WO2014046544A1
(en)
|
2012-09-21 |
2014-03-27 |
Aapa B.V. |
Substituted 3-heteroaryloxy-3-(hetero)aryl-propylamines as serotonin transporter and serotonin ht2c receptor modulators
|
|
BR112016022575A2
(pt)
|
2014-03-28 |
2017-08-15 |
Azevan Pharmaceuticals Inc |
Composições e métodos para o tratamento de doenças neurodegenerativas
|
|
CN105777706B
(zh)
*
|
2014-12-25 |
2019-08-23 |
江苏恩华药业股份有限公司 |
一种3-[(苯并[d][1, 3]二氧戊环-4-基)-氧基]-3-芳基丙胺类化合物及其应用
|
|
AU2018333051B2
(en)
|
2017-09-15 |
2024-03-21 |
Azevan Pharmaceuticals, Inc. |
Compositions and methods for treating brain injury
|
|
CA3145388A1
(en)
|
2019-07-19 |
2021-01-28 |
Bioxcel Therapeutics, Inc. |
Non-sedating dexmedetomidine treatment regimens
|
|
US11806334B1
(en)
|
2023-01-12 |
2023-11-07 |
Bioxcel Therapeutics, Inc. |
Non-sedating dexmedetomidine treatment regimens
|
